| Schedule of quarterly financial Data (Unaudited) |
Consolidated Balance Sheet – As of June 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | SAFE Notes subscription receivable | | $ | — | | $ | 33,000 | | $ | 33,000 | Total assets | | $ | 4,926,231 | | $ | 33,000 | | $ | 4,959,231 | Liabilities | | | | | | | | | | SAFE Notes | | $ | 20,463,632 | | $ | (4,917,505) | | $ | 15,546,127 | Total liabilities | | $ | 20,564,519 | | $ | (4,917,505) | | $ | 15,647,014 | Total stockholders’ deficit | | $ | (15,638,288) | | $ | 4,950,505 | | $ | (10,687,783) |
Consolidated Balance Sheet – As of September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | SAFE Notes subscription receivable | | $ | — | | $ | 28,000 | | $ | 28,000 | Total assets | | $ | 30,524,544 | | $ | 28,000 | | $ | 30,552,544 | Liabilities | | | | | | | | | | SAFE Notes | | $ | — | | $ | — | | $ | — | Total liabilities | | $ | 605,325 | | $ | 138,977 | | $ | 744,302 | Total stockholders’ equity | | $ | 29,919,219 | | $ | (110,977) | | $ | 29,808,242 |
Consolidated Statement of Operations – For the six months ended June 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 752,535 | | $ | 892,601 | | $ | 1,645,136 | Research and development expenses | | $ | 135,930 | | $ | 77,832 | | $ | 213,762 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (1,251,721) | | $ | 1,409,741 | | $ | 158,020 | Net loss | | $ | (2,129,151) | | $ | 439,308 | | $ | (1,689,843) | Basic and diluted weighted average shares outstanding of common stock | | | 658,569 | | | 4,826,068 | | | 5,484,637 | Basic and diluted net loss per share of common stock | | $ | (3.23) | | $ | 2.92 | | $ | (0.31) |
Consolidated Statement of Operations – For the three months ended September 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 486,151 | | $ | 101,016 | | $ | 587,167 | Research and development expenses | | $ | 219,478 | | $ | (72,754) | | $ | 146,724 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (1,248,279) | | $ | 752,928 | | $ | (495,351) | Net loss | | $ | (1,944,963) | | $ | 724,667 | | $ | (1,220,296) | Basic and diluted weighted average shares outstanding of common stock | | | 16,182,268 | | | (2,992,451) | | | 13,189,817 | Basic and diluted net loss per share of common stock | | $ | (0.12) | | $ | 0.03 | | $ | (0.09) |
Consolidated Statement of Operations – For the nine months ended September 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 1,238,686 | | $ | 993,617 | | $ | 2,232,303 | Research and development expenses | | $ | 355,408 | | $ | 5,078 | | $ | 360,486 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (2,500,000) | | $ | 2,162,669 | | $ | (337,331) | Net loss | | $ | (4,074,114) | | $ | 1,163,975 | | $ | (2,910,139) | Basic and diluted weighted average shares outstanding of common stock | | | 13,006,041 | | | (4,329,737) | | | 8,676,304 | Basic and diluted net loss per share of common stock | | $ | (0.31) | | $ | (0.02) | | $ | (0.33) |
Consolidated Statement of Operations – For the six months ended June 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 2,718,780 | | $ | (450,018) | | $ | 2,268,762 | Research and development expenses | | $ | 780,517 | | $ | 769,258 | | $ | 1,549,775 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (3,638,167) | | $ | 519,225 | | $ | (3,118,942) | Net loss | | $ | (7,136,460) | | $ | 199,985 | | $ | (6,936,475) | Basic and diluted weighted average shares outstanding of common stock | | | 16,237,748 | | | (2,180,399) | | | 14,057,349 | Basic and diluted net loss per share of common stock | | $ | (0.44) | | $ | (0.05) | | $ | (0.49) |
Consolidated Statement of Operations – For the three months ended September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 6,700,416 | | $ | 93,626 | | $ | 6,794,042 | Research and development expenses | | $ | 2,104,021 | | $ | (183,649) | | $ | 1,920,372 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (31,601,632) | | $ | (5,113,475) | | $ | (36,715,107) | Net loss | | $ | (40,390,883) | | $ | (5,023,452) | | $ | (45,414,335) | Basic and diluted weighted average shares outstanding of common stock | | | 31,316,149 | | | (7,881,883) | | | 23,434,266 | Basic and diluted net loss per share of common stock | | $ | (1.29) | | $ | (0.65) | | $ | (1.94) |
Consolidated Statement of Operations – For the nine months ended September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Operating expenses: | | | | | | | | | | General and administrative expenses | | $ | 9,419,196 | | $ | (356,392) | | $ | 9,062,804 | Research and development expenses | | $ | 2,884,538 | | $ | 585,609 | | $ | 3,470,147 | Other non-operating income (expense): | | | | | | | | | | Change in fair value of SAFE notes | | $ | (35,239,799) | | $ | (4,594,250) | | $ | (39,834,049) | Net loss | | $ | (47,527,343) | | $ | (4,823,467) | | $ | (52,350,810) | Basic and diluted weighted average shares outstanding of common stock | | | 21,282,445 | | | (3,891,242) | | | 17,391,203 | Basic and diluted net loss per share of common stock | | $ | (2.23) | | $ | (0.78) | | $ | (3.01) |
Consolidated Statement of stockholders’ equity (deficit) for six months ended June 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at December 31, 2023 | | $ | (630,192) | | $ | 1,090,453 | | $ | 460,261 | Stock-based compensation | | | 140,730 | | | 965,135 | | | 1,105,865 | Net loss | | | (2,129,151) | | | 439,308 | | | (1,689,843) | Balance at June 30, 2024 | | $ | (2,618,613) | | $ | 2,494,896 | | $ | (123,717) |
Consolidated Statement of stockholders’ equity (deficit) for nine months ended September 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at December 31, 2023 | | $ | (630,192) | | $ | 1,090,453 | | $ | 460,261 | Stock-based compensation | | | 145,273 | | | 993,302 | | | 1,138,575 | Net loss | | | (4,074,114) | | | 1,163,975 | | | (2,910,139) | Balance at September 30, 2024 | | $ | (4,559,033) | | $ | 3,247,730 | | $ | (1,311,303) |
Consolidated Statement of stockholders’ equity (deficit) for three months ended September 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at June 30, 2024 | | $ | (2,618,613) | | $ | 2,494,896 | | $ | (123,717) | Stock-based compensation | | | 4,543 | | | 28,167 | | | 32,710 | Net loss | | | (1,944,963) | | | 724,667 | | | (1,220,296) | Balance at September 30, 2024 | | $ | (4,559,033) | | $ | 3,247,730 | | $ | (1,311,303) |
Consolidated Statement of stockholders’ equity (deficit) for six months ended June 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at December 31, 2024 | | $ | (8,513,101) | | $ | 4,431,280 | | $ | (4,081,821) | Stock-based compensation | | | 11,273 | | | 216,400 | | | 227,673 | Net loss | | | (7,136,460) | | | 199,985 | | | (6,936,475) | Balance at June 30, 2025 | | $ | (15,638,288) | | $ | 4,847,665 | | $ | (10,790,623) |
Consolidated Statement of stockholders’ equity (deficit) for nine months ended September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at December 31, 2024 | | $ | (8,513,101) | | $ | 4,431,280 | | $ | (4,081,821) | Stock-based compensation | | | 5,567,153 | | | 97,296 | | | 5,664,449 | Issuance of Common Stock upon conversion of SAFE Notes | | | 53,328,419 | | | 182,815 | | | 53,511,234 | Net loss | | | (47,527,343) | | | (4,823,467) | | | (52,350,810) | Balance at September 30, 2025 | | $ | 29,919,219 | | $ | (110,977) | | $ | 29,808,242 |
Consolidated Statement of stockholders’ equity (deficit) for three months ended September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Balance at June 30, 2025 | | $ | (15,638,288) | | $ | 4,848,486 | | $ | (10,789,802) | Stock-based compensation | | | 5,555,880 | | | (119,104) | | | 5,436,776 | Issuance of Common Stock upon conversion of SAFE Notes | | | 53,328,419 | | | 182,815 | | | 53,511,234 | Net loss | | | (40,390,883) | | | (5,023,451) | | | (45,414,334) | Balance at September 30, 2025 | | $ | 29,919,219 | | $ | (110,977) | | $ | 29,808,242 |
Consolidated Statement of cash flows for the six months ended June 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Cash flows from operating activities: | | | | | | | | | | Net loss | | $ | (2,129,151) | | $ | 439,308 | | $ | (1,689,843) | Change in fair value of SAFE Notes | | | 1,251,721 | | | (1,409,741) | | | (158,020) | Stock-based compensation | | | 135,432 | | | 970,433 | | | 1,105,865 |
Consolidated Statement of cash flows for the nine months ended September 30, 2024 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Cash flows from operating activities: | | | | | | | | | | Net loss | | $ | (4,074,114) | | $ | 1,163,975 | | $ | (2,910,139) | Change in fair value of SAFE Notes | | | 2,500,000 | | | (2,004,649) | | | 495,351 | Stock-based compensation | | | 139,880 | | | 998,695 | | | 1,138,575 |
Consolidated Statement of cash flows for the six months ended June 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Cash flows from operating activities: | | | | | | | | | | Net loss | | $ | (7,136,460) | | $ | 199,985 | | $ | (6,936,475) | Change in fair value of SAFE Notes | | | 3,638,167 | | | (519,225) | | | 3,118,942 | Stock-based compensation | | | 10,452 | | | 217,221 | | | 227,673 |
Consolidated Statement of cash flows for the nine months ended September 30, 2025 | | | | | | | | | | | | As Previously Reported | | Adjustment | | As Restated | Cash flows from operating activities: | | | | | | | | | | Net loss | | $ | (47,527,343) | | $ | (4,823,467) | | $ | (52,350,810) | Change in fair value of SAFE Notes | | | 35,239,799 | | | 4,594,250 | | | 39,834,049 | Stock-based compensation | | | 5,567,153 | | | 97,296 | | | 5,664,449 |
|